Table 1 Clinicopathologic characteristics of patients in non-pCR and pCR cohorts
Characteristics | pCR (n = 155) | Non-pCR (n = 441) | P-value |
|---|---|---|---|
Age | Â | Â | 0.448 |
 Mean ± SD | 52.52 ± 9.17 | 53.17 ± 9.24 |  |
BMI | Â | Â | 0.255 |
 Mean ± SD | 24.62 ± 3.29 | 24.97 ± 3.43 |  |
Menopausal status | Â | Â | 0.935 |
 Pre/peri-menopausal | 42 (27.1%) | 121 (27.4%) |  |
 Post-menopausal | 113 (72.9%) | 320 (72.6%) |  |
Tumor size | Â | Â | Â |
 Mean ± SD | 29.35 ± 10.41 | 29.63 ± 8.48 | 0.765 |
T stage | Â | Â | 0.278 |
 T1 | 28 (18.1%) | 59 (13.4%) |  |
 T2 | 119 (76.8%) | 367 (83.2%) |  |
 T3 | 5 (3.2%) | 7 (1.6%) |  |
 T4 | 3 (1.9%) | 8 (1.8%) |  |
Phenotypes | Â | Â | <0.001 |
 HR+/HER2− | 22 (14.2%) | 289 (65.5%) |  |
 Triple-negative | 30 (19.4%) | 48 (10.9%) |  |
 HR−/HER2+ | 64 (41.3%) | 44 (10.0%) |  |
 HR+/HER2+ | 39 (25.2%) | 60 (13.6%) |  |
Receptor status | Â | Â | Â |
ER | Â | Â | <0.001 |
 Negative | 99 (63.9%) | 100 (22.7%) |  |
 Low positive | 13 (8.4%) | 8 (1.8%) |  |
 Positive | 43 (27.7%) | 333 (75.5%) |  |
PR | Â | Â | <0.001 |
 Negative | 112 (72.3%) | 302 (68.5%) |  |
 Positive | 43 (27.7%) | 139 (31.5%) |  |
HER2 | Â | Â | <0.001 |
 Negative | 30 (19.4%) | 119 (27.0%) |  |
 Low expression | 22 (14.2%) | 218 (49.4%) |  |
 Positive | 103 (66.5%) | 104 (23.6%) |  |
Ki-67(%) | Â | Â | Â |
 Mean ± SD | 40.68 ± 19.59 | 27.35 ± 19.50 | <0.001 |
Clinical TNM stage | Â | Â | 0.006 |
 I–II | 118 (76.1%) | 378 (85.7%) |  |
 III | 37 (23.9%) | 63 (14.3%) |  |
Nodal status | Â | Â | 0.521 |
 Node positive | 144 (92.9%) | 416 (94.3%) |  |
 Node negative | 11 (7.1%) | 25 (5.7%) |  |
Chemotherapy regimen | Â | Â | <0.001 |
 Use of anti-HER2 agents in HER2-positive cancer | 90 (58.1%) | 76 (17.2%) |  |
 Taxane- and platinum-based | 8 (5.2%) | 15 (3.4%) |  |
 Taxane-based | 2 (1.3%) | 10 (2.3%) |  |
 Anthracycline with taxane | 55 (35.5%) | 340 (77.1%) |  |
Multifocal | Â | Â | 0.291 |
 Yes | 23 (14.8%) | 82 (18.6%) |  |
 No | 132 (85.2%) | 359 (81.4%) |  |
BI-RADS | Â | Â | 0.005 |
 2, 3, 4a | 4 (2.6%) | 4 (0.9%) |  |
 4b | 15 (9.7%) | 18 (4.1%) |  |
 4c | 41 (26.5%) | 164 (37.2%) |  |
 5 | 95 (61.3%) | 255 (57.8%) |  |
